4D 310
Alternative Names: 4D-310Latest Information Update: 18 Feb 2024
At a glance
- Originator 4D Molecular Therapeutics
- Class Gene therapies
- Mechanism of Action Alpha-galactosidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Fabry's disease
Most Recent Events
- 12 Feb 2024 Interim pharmacodynamics, efficacy, and adverse events data from the phase I/II INGLAXA trial in Fabry's disease released by 4D Molecular Therapeutics
- 08 Jan 2024 4D Molecular Therapeutics anticipates FDA submission of data from the non-human primate (NHP) study of 4D-310 with the rituximab/sirolimus in Q2 2024
- 30 Oct 2023 4DMT expects to submit the phase I/II trial results to the FDA in Q2 2024